Q1-2012 US refractive surgeries continued to trend upward, though performance was mixed, and forecasts are fluctuating.
Q1-2012 US IOL procedure volume grew more briskly than in recent years, climbing 5.2 percent.
ARVO met in Fort Lauderdale for the last scheduled time and offered a full agenda of present-day ophthalmic concerns and future treatment potentials. Topics included:
CATT & IVAN
More on Anti-VEGFs
Reports from IVAN & CATT studies confirm equivalency of Lucentis and Avastin.
Global revenue share for premium IOLs is expected to grow to nearly half of revenue for all IOLs over the next five years.
This month's news include the latest from Novartis, Bayer Yakuhin, Santen Pharmaceuticals Co., Ltd., Oraya Therapeutics, Inc., Hoya Surgical Optics Inc., Bausch + Lomb, and Abott Medical Optics.
You are not currently logged in.
©2018 Market Scope
Lost your Password